Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.62 |
| ▸ | HTR1A | P08908 | 6/20 | 0.62 |
| ▸ | HTR6 | P50406 | 6/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.41 |
| ▸ | FEN1 | P39748 | 3/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6709392 | 0.81 | FEN1 (0.43) | SLC6A2SLC6A4SLC6A3HTR1AALOX5AP | |
| SCHEMBL6794310 | 0.79 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3HTR1AHTR6 | |
| SCHEMBL5899901 | 0.79 | ENPP2 (0.46) | SLC6A2SLC6A4SLC6A3HTR1APRMT5 | |
| SCHEMBL5937367 | 0.78 | HTR2C (0.45) | SLC6A2SLC6A4SLC6A3HTR1AALOX5AP | |
| SCHEMBL5899843 | 0.77 | ADRA1D (0.45) | SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL5899905 | 0.75 | S1PR5 (0.46) | HTR6RXRARXRBRXRG | |
| SCHEMBL5899861 | 0.74 | DRD2 (0.48) | HTR1A | |
| SCHEMBL5899857 | 0.73 | MEN1 (0.36) | SLC6A2SLC6A4SLC6A3HTR1AHTR6 | |
| SCHEMBL23228732 | 0.72 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3HTR1AHTR6 | |
| SCHEMBL21806587 | 0.72 | MAOA (0.46) | RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122432-A1 | Aryl piperidine derivatives and use thereof to reduce elevated levels of ldl-cholesterol | GLAXO GROUP LIMITED (GB) | 2006-06-08 | — | — | US | disclosed |
| EP-1534280-A1 | ARYL PIPERIDINE DERIVATIVES AND USE THEREOF TO REDUCE ELEVATED LEVELS OF LDL-CHOLESTEROL | GLAXO GROUP LIMITED (GB) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004006923-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | GLAXO GROUP LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004006924-A1 | ARYL PIPERIDINE DERIVATIVES AND USE THEREOF TO REDUCE ELEVATED LEVELS OF LDL-CHOLESTEROL | GLAXO GROUP LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122432-A1 | Aryl piperidine derivatives and use thereof to reduce elevated levels of ldl-cholesterol | LDLR, NR1H2, NR1H3 | SLC6A2 3311/4885SLC6A4 2596/4885SLC6A3 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.